Thiogenesis Therapeutics, Corp. TTIPF
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -34.32% | 10.09% | -13.32% | 71.21% | 38.64% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -19.34% | -33.09% | 32.03% | 249.85% | 147.99% |
| Operating Income | 19.34% | 33.09% | -32.03% | -249.85% | -147.99% |
| Income Before Tax | 21.62% | 32.38% | -54.30% | -259.41% | -188.42% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 21.62% | 32.38% | -54.30% | -259.41% | -188.42% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 21.62% | 32.38% | -54.30% | -259.41% | -188.42% |
| EBIT | 19.34% | 33.09% | -32.03% | -249.85% | -147.99% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 37.16% | 40.19% | -35.80% | -226.42% | -181.90% |
| Normalized Basic EPS | 37.30% | 40.30% | -36.36% | -227.27% | -184.62% |
| EPS Diluted | 37.16% | 40.19% | -35.80% | -226.42% | -181.90% |
| Normalized Diluted EPS | 37.30% | 40.30% | -36.36% | -227.27% | -184.62% |
| Average Basic Shares Outstanding | 24.86% | 12.63% | 13.37% | 10.09% | 1.78% |
| Average Diluted Shares Outstanding | 24.86% | 12.63% | 13.37% | 10.09% | 1.78% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |